Leitat Purchases ReadyCell through MedTech Innovation on Advanced Medicine

Leitat strengthens its biotechnology direction. The technology company has strengthened its leadership position with the acquisition of ReadyCell through MedTech Innovation on Advanced Medicine (MedTech Barcelona), a biotechnology company dedicated to the development of healthcare and pharmaceutical solutions.

ReadyCell marketed products developed together with Leitat

This operation is the result of a long-standing collaboration between Leitat and ReadyCell, who since 2011 have jointly developed products that the latter subsequently marketed internationally.

With this acquisition, MedTech Barcelona is promoting the development and sale of cell kits that facilitate in vitro testing by companies and research laboratories using advanced technologies that reduce the use of animals and improve the reproducibility and precision of results.

This company offers a range of special products and services, including permeability and drug-transporter interaction studies; drug toxicity and metabolism models; anti-inflammatory properties of new compounds; and collaboration in the development of new cell models and/or kits.

MedTech Barcelona offers its products to more than a hundred pharmaceutical, biotechnology and academic clients

Furthermore, MedTech Barcelona’s proprietary patented technology and acquired capabilities allow for prolonged stability of cell cultures in its kits, helping their transport and preservation at room temperature without compromising cell viability and functionality. This is very useful for laboratories that do not have immediate access to cell culture facilities, allowing tests to be carried out in perfect conditions.

MedTech Barcelona has a distribution network that includes markets such as Europe, the United States, Japan and India, assuming that the entire staff dedicated to the research and marketing of cell kits is integrated into MedTech Barcelona, ​​located in the Barcelona Science Park.

“With this acquisition, through MedTech Barcelona, ​​we are strengthening our commitment to development and innovation in biotechnology to continue growing and maintaining our leadership in the sector,” said Jordi Cabrafiga, CEO of Leitat. He added that “we are adding ReadyCell’s knowledge and experience to the company, which will allow us to continue providing high added value solutions to our clients.”

__

(Featured image by Belova59 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us